Company news

Jasper Therapeutics, Inc. news in 2025

Jasper Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

December 2, 2025

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

December 1, 2025

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 10, 2025

Jasper Therapeutics to Present at Upcoming Investor Conferences

November 4, 2025

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

September 18, 2025

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

September 18, 2025

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

July 9, 2025

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

July 7, 2025

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

June 14, 2025

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

June 3, 2025

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

March 1, 2025

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

February 28, 2025

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

February 27, 2025

Jasper Therapeutics to Present at Upcoming March Investor Conferences

February 25, 2025

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

February 9, 2025

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

January 7, 2025

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

January 5, 2025

Decks in 2025